Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14004740 | 1.00 | FFAR1 (0.48) | FFAR1AKR1B1PTPN1MMECTSL | |
| Hydrochloric Acid SCHEMBL3473569 | 0.99 | FFAR1 (0.47) | FFAR1AKR1B1PTPN1MMECTSL | |
| Hydrochloric Acid SCHEMBL2728 | 0.99 | FFAR1 (0.47) | FFAR1AKR1B1PTPN1MMECTSL | |
| SCHEMBL8813467 | 0.90 | FFAR1 (0.44) | FFAR1AKR1B1PTPN1MMECTSL | |
| SCHEMBL2565791 | 0.90 | FFAR1 (0.43) | FFAR1AKR1B1PTPN1MMECTSL | |
| SCHEMBL2432 | 0.89 | MYC (0.45) | FFAR1AKR1B1PTPN1MMEMYC | |
| SCHEMBL8065614 | 0.89 | MYC (0.45) | FFAR1AKR1B1PTPN1MMEMYC | |
| SCHEMBL2174 | 0.89 | MYC (0.45) | FFAR1AKR1B1PTPN1MMEMYC | |
| SCHEMBL2437416 | 0.88 | CTSS (0.42) | PTPN1CTSLCTSBCTSSCTSK | |
| Oxalic Acid SCHEMBL1616541 | 0.88 | MME (0.44) | FFAR1AKR1B1PTPN1MMEMYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | claimed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | claimed |
| EP-2260018-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | Hetero Research Foundation (IN) | 2010-12-15 | — | — | EP | claimed |
| WO-2009125416-A2 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-15 | — | — | WO | claimed |
| JP-11322697-A | — | — | None | — | — | JP | disclosed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-8492577-B2 | Process for preparation of valsartan intermediate | HETERO RESEARCH FOUNDATION (IN) | 2013-07-23 | — | — | US | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2011-09-29 | — | — | US | disclosed |
| US-7943794-B2 | Processes for the preparation of intermediates of valsartan | RANBAXY LABORATORIES LIMITED (IN) | 2011-05-17 | — | — | US | disclosed |
| US-7943794-B2 | Processes for the preparation of intermediates of valsartan | RANBAXY LABORATORIES LIMITED (IN) | 2011-05-17 | — | — | US | disclosed |
| WO-2005049588-A1 | PROCESS FOR ISOLATION OF VALSARTAN | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| JP-H11322697-A | PRODUCTION OF, N-((2'-CYANOBIPHENYL-4-YL)METHYL)-L-VALINE BENZYL ESTER AND NEW SALT OF THE SAME COMPOUND | SUMIKA FINE CHEMICALS CO LTD | 1999-11-24 | — | — | JP | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237822-A1 | PROCESS FOR PREPARATION OF VALSARTAN INTERMEDIATE | REN, AGT, ACE | FFAR1 2643/4885AKR1B1 139/4885PTPN1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.